OCALA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (AIM) (NYSE American: AIM) (“AIM” or the “Company”) today announced Safety Committee approval to proceed with the Phase 2 portion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results